![Michael Jerman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Jerman
Direktor/Vorstandsmitglied bei
HEDGEPATH PHARMACEUTICALS INC
Vermögen: 51 274 $ am 31.05.2026
Profil
Mr. Michael A. Jerman is an Independent Director at Alaunos Therapeutics, Inc., an Independent Director at Inhibitor Therapeutics, Inc. and a Managing Partner at Hollywell Partners LLC.
He is on the Board of Directors at Alaunos Therapeutics, Inc. and Inhibitor Therapeutics, Inc. Mr. Jerman was previously employed as an Independent Director by MIRA Pharmaceuticals, Inc. and an Independent Director by Telomir Pharmaceuticals, Inc. He also served on the board at PricewaterhouseCoopers LLP.
He received his undergraduate degree from the University of South Florida, a graduate degree from The University of Tampa, Inc. and an MBA from the University of Oxford.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.04.2026 | 15’621 ( 0.64% ) | 44 520 $ | 31.05.2026 | |
| 01.04.2025 | 80’411 ( 0.05% ) | 6 755 $ | 31.05.2026 |
Aktive Positionen von Michael Jerman
| Unternehmen | Position | Beginn |
|---|---|---|
| HEDGEPATH PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | 24.05.2023 |
| ALAUNOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.07.2025 |
HOLLYWELL PARTNERS LLC
 HOLLYWELL PARTNERS LLC Miscellaneous Commercial ServicesCommercial Services Operates as a financial company that provides strategy to enhance business growth for organization services | Corporate Officer/Principal | 01.05.2019 |
Ehemalige bekannte Positionen von Michael Jerman
| Unternehmen | Position | Ende |
|---|---|---|
| TELOMIR PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 18.11.2024 |
| MIRA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 18.11.2024 |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, assurance, consulting and tax & business consulting services | Direktor/Vorstandsmitglied | 01.08.2019 |
Ausbildung von Michael Jerman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, assurance, consulting and tax & business consulting services | Commercial Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of South Florida
 University of South Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Tampa, Inc.
 The University of Tampa, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Inhibitor Therapeutics, Inc.
 Inhibitor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
MIRA Pharmaceuticals, Inc.
 MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
HOLLYWELL PARTNERS LLC
HOLLYWELL PARTNERS LLC Miscellaneous Commercial ServicesCommercial Services Operates as a financial company that provides strategy to enhance business growth for organization services | Commercial Services |
Telomir Pharmaceuticals, Inc.
 Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
